Rezolve AI arrives at its October 6 earnings print in a position that has deteriorated since the last notes were filed: the stock has fallen another 7% from the $2.34 level cited a week ago, short interest remains structurally heavy, and the question management must now answer is whether a $60M cost-reduction programme announced last week can survive contact with a sceptical market.
The positioning picture has softened slightly at the margins but the bears are not retreating in any meaningful way. Short interest closed September at 13.8% of free float, a fractional pullback from the 16% peak seen earlier in September but still roughly 16% larger than it was a month ago. The monthly build is what matters: shorts accumulated through August, absorbed the borrow spike that sent cost to borrow to 71.8% on September 9, and have held through the subsequent normalisation. Borrowing costs now run at 19.4%, down about 12% on the week but still 59% above where they were a month ago. Availability has loosened slightly to 24%, up from a trough near 18% earlier in September, but that still means only one share is available to lend for every four already out. The ORTEX short score sits at 78.9, one of the highest readings in the entire universe, ranking in the second percentile on the short score factor. Bears are expensive to maintain and they are staying.
Options positioning offers no particular counterweight to that bearish lean. The put/call ratio is at 0.25, essentially flat against its 20-day average of 0.249 and a z-score of just 0.33, meaning the options market is not pricing in heightened fear ahead of the print. The 52-week PCR range runs from 0.11 to 0.33, and current readings are in the middle of that band. Call open interest is running well above put open interest. That is not a sign of bullish conviction so much as an absence of defensive hedging, which is itself notable given the stock is 27% lower over the past month.
The ownership structure adds another layer to watch. CEO Daniel Wagner filed a Schedule 13D amendment in August disclosing a stake of 13.8%, down from 15.6% previously, but still on the 13D register, which marks him as an activist filer with stated intent. Wagner also executed open-market purchases in April at $4.00 per share, spending over $3.25M across two transactions, a price that is now 45% above where the stock trades. That purchase is now deeply underwater. Alejandro Gonzalez holds 7.5% per his July 2026 13G/A filing, up from 5.7%, making him the only large holder on the register who has been actively adding. Alyeska Investment Group trimmed from 7.57% to 4.44% in February, dropping below the 5% threshold, which under the disclosure rules cited means that position may have changed further without a new filing obligation. As-of dates matter here: stakes are as last disclosed and holders dropping below 5% may exit without further reporting.
The earnings history provides the starkest context for what October 6 means to this tape. The last print on September 1 sent the stock down 19.4% in one session and 20.1% over the following week. The release before that, in August, produced a 0.7% one-day move before a 2.2% five-day decline. A two-print sample is thin, but the directional skew is clear: the market has punished rather than rewarded results. The $60M cost programme and the FY2026 guidance of $360M in sales, affirmed on September 1, now need a result that credibly bridges those two commitments. Among peers this week, HKD gained 5.3% and CYN added 5.2% while REKR fell 13.9%, so the AI and small-cap software cohort is moving in opposite directions rather than offering RZLV any group momentum.
What to watch on October 6 is less whether Rezolve is growing and more whether management can demonstrate that the cost-reduction programme is funded by structural change rather than a reduction in investment capacity, and whether the revenue trajectory is consistent with the $360M full-year target with only one quarter left in the fiscal year.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
